Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19538076 | 0.83 | POLB (0.40) | EGLN1TSHRALDH1A1LMNATDP1 | |
| SCHEMBL21946049 | 0.82 | TSHR (0.40) | TSHRALDH1A1LMNAMAPTSLC6A2 | |
| SCHEMBL7826698 | 0.80 | MAOA (0.36) | ALDH1A1TDP1SLC6A2SLC6A4MEN1 | |
| SCHEMBL6627746 | 0.80 | EGLN1 (0.39) | EGLN1TSHRALDH1A1LMNAMAPT | |
| SCHEMBL6896024 | 0.78 | EGLN1 (0.38) | EGLN1TSHRALDH1A1LMNAMAPT | |
| SCHEMBL7015641 | 0.77 | EGLN1 (0.55) | EGLN1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL7441120 | 0.75 | GAA (0.46) | ALDH1A1MAPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL7290876 | 0.74 | — | — | |
| SCHEMBL27866694 | 0.74 | APAF1 (0.38) | SLC6A2SLC6A4MEN1KMT2ASLC1A3 | |
| SCHEMBL7285688 | 0.74 | CA2 (0.37) | MEN1KMT2ACYP2D6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113769086-A | Targeted therapeutic drug, preparation method and application thereof | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 2021-12-10 | — | — | CN | claimed |
| CN-113750257-A | Tumor targeted imaging material, preparation method and application thereof | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 2021-12-07 | — | — | CN | claimed |
| CN-113750247-A | Tumor targeting drug, preparation method and application thereof | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 2021-12-07 | — | — | CN | claimed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-113769086-A | Targeted therapeutic drug, preparation method and application thereof | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 2021-12-10 | — | — | CN | disclosed |
| CN-113750257-A | Tumor targeted imaging material, preparation method and application thereof | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 2021-12-07 | — | — | CN | disclosed |
| CN-113750247-A | Tumor targeting drug, preparation method and application thereof | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 2021-12-07 | — | — | CN | disclosed |
| CN-110573499-A | inhibitors of α v β 6 integrin | 莫菲克医疗股份有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2324041-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010019511-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-0643072-B1 | 2-Piperazinone compounds and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-02-24 | — | — | EP | disclosed |
| US-5550131-A | ANTITHROMBOTIC AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| EP-0643072-A1 | 2-Piperazinone compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | EGLN1 3637/4885TSHR 4317/4885ALDH1A1 3493/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | EGLN1 3449/4885TSHR 2000/4885ALDH1A1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.